DRD1 and bone disorder: We provide the first evidence demonstrating a functional connection between Madopar and DRD1 in the context of GC‐associated ONFH, suggesting that DRD1 is a promising potential therapeutic target for apoptosis‐driven bone disorders and that Madopar serves as a potential restrictor of progressive GC‐associated ONFH.